Overview

Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer

Status:
Completed

Trial end date:
2017-10-30

Target enrollment:

Participant gender:

Summary

National, randomized, unblinded, phase IIb trial with 2 strata: First-line chemotherapy / Second-line chemotherapy for locally recurrent or metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Oscar Lambret

Collaborator:

Boehringer Ingelheim

Treatments:

Docetaxel
Nintedanib